WATERTOWN, Mass.--(BUSINESS WIRE)--Drug delivery company pSivida Corp. (NASDAQ:PSDV) (ASX:PVA) today announced the opening of an investigational new drug application (IND) for a Phase I/II clinical trial to study pSivida’s injectable, sustained release insert delivering the corticosteroid fluocinolone acetonide (FAc) for the treatment of uveitis affecting the posterior segment of the eye (posterior uveitis). An insert of the same design is being developed for the treatment of diabetic macular edema (DME) by pSivida’s licensee, Alimera Sciences, using Alimera’s ILUVIEN® brand name.
